Derivation of Targeted Phage Vectors for Gene Therapy of Prostate Cancer
Abstract
The subject of these studies is the development of targeted vector for selective infection and killing of prostate cancer cells. The resultant vector is to be administered to prostate cancer patients to find, infect and destroy tumor cells. Targeting of the vector to prostate tumors is to be accomplished via incorporation into its capsid of ligands, which selectively bind to prostate specific membrane antigen (PSMA). Research accomplishments: (i) two targets, recombinant sPSMA protein and 293/PSMA cells, have been developed for identification of PSMA-specific peptides; (ii) a panel of monoclonal anti-PSMA antibodies has been derived; (iii) a single chain (scFv) version of one of these mAbs has been incorporated into a filamentous phage; (iv) an ELISA-based screening procedure has been established; (v) two scFv-targeted phage vectors each expressing either GFP or HSV tk.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2006
- Accession Number
- ADA462846
Entities
People
- Victor Krasnykh
Organizations
- The University of Texas MD Anderson Cancer Center